Articles written by: Jaime Hannula

Dicerna Pharmaceuticals Doses First Patient with DCR-PHXC in Phase 1 Clinical Trial

Dicerna Pharmaceuticals Doses First Patient with DCR-PHXC in Phase 1 Clinical Trial

Dicerna Pharmaceuticals (DRNA) said Wednesday it has dosed the first primary hyperoxaluria (PH) patient with DCR-PHXC in a phase 1 clinical trial. DCR-PHXC is an investigational GalXC product candidate in development for the treatment of all forms of PH, a family of severe, rare, inherited disorders of the liver that often result in kidney failure. The company also announced that […]

Lilis Energy Sees Record Initial Production From Wolfcamp Well

Lilis Energy Sees Record Initial Production From Wolfcamp Well

Lilis Energy (LLEX), an exploration and development company, is up more than 5% in pre-market trading as the company said one of its wells reached record initial production. The company said its Hippo #2H is the highest recorded initial production, or IP, per 1,000 ft. the company has drilled to date in the Wolfcamp formation in the Permian basin and […]

Movado Group Rises More Than 9% Premarket After Posting Q1 Adjusted EPS

Movado Group Rises More Than 9% Premarket After Posting Q1 Adjusted EPS

Shares of Movado Group (MOV), the Swiss watchmaking company, rose more than 9% in premarket trade after it posted Q1 adjusted EPS of $0.37 compared with $0.01 a year earlier and beating the $0.11 average estimate by analysts in a Capital IQ poll. Net sales in the quarter ended April 30 increased 28.1% to $127.1 million from $99.3 million a […]

Celgene to Present Data From More Than 60 Cancer Therapy Studies

Celgene to Present Data From More Than 60 Cancer Therapy Studies

Celgene (CELG), the biotechnology company, said that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating its experimental therapies will be presented at the American Society of Clinical Oncology Annual Meeting between June 1-5 in Chicago. “Cancer research is at a critical point where advances in cellular immunotherapy may be able to drive previously unattainable advancements,” […]

Extreme Networks Adds 3% on Insider Buying

Extreme Networks Adds 3% on Insider Buying

Extreme Networks (EXTR) rose about 3% after regulatory filings showed insiders buying shares. President and CEO Edward Meyercord bought 20,000 shares at $8.42 each on Monday and EVP of worldwide sales services Robert Gault exercised some performance and RSU-based options. Additionally, director Edward Kennedy bought 50,000 shares over the past couple of days, including 45,183 at $8.613 each, and another […]

Enersys Adds 2% – Sees Q4 Above Street

Enersys Adds 2% – Sees Q4 Above Street

Enersys (ENS) rose 2% after the company said it expects Q4 net EPS of $1.27, up from $0.76 in the year-ago period and above the CapIQ mean for $1.20, GAAP. Non-GAAP EPS are seen at $1.24, down from $1.28 last year but a penny above the normalized estimate. Net sales rose 9% to $683.0 million from last year and beat […]

Broadridge Financial Solutions Posts Fiscal Q3 Beat

Broadridge Financial Solutions Posts Fiscal Q3 Beat

Broadridge Financial Solutions (BR) reported Tuesday financial results for fiscal Q3, with earnings and revenue that topped analysts’ expectations; it also provided guidance for fiscal 2018. The provider of investor communications posted adjusted earnings of $1 per share, compared with the prior-year period’s $0.69 per share. Analysts polled by Capital IQ were expecting EPS of $0.79. Revenue was $1.07 billion, […]